Study phase 3 trial evaluating the antiviral drug as potential therapy for mild to moderate COVID-19 in adult outpatients who are not requiring hospitalization, who had a positive COVID-19 test within 72 hours of study enrollment.
Study subjects should meet all of the following criteria:
1. Adults age 18 or older
2. Tested positive for SARS-CoV-2 by RT-PCR assay (first positive test) collected within 72 hours of randomization.
3. Stated willingness to give their written informed consent to participate in the study.
4.Females must be unable to bear children, OR ensure that their male partner is incapable of fathering a child, OR, if of childbearing potential will strictly adhere to contraceptive measures during the study and for seven days following the last dose of study medication (as detailed in section 5.8)
5. Females must agree to stop breast-feeding prior to first dose of study drug and through seven days after completing therapy
6. Females must have a negative pregnancy test at screening
7. Ability to take oral medication and be willing to adhere the pills.